atracurium

Names

[ CAS No. ]:
64228-79-1

[ Name ]:
atracurium

[Synonym ]:
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
2,2'-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
Isoquinolinium, 2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-
Atracurium
2,2'-{Pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
UNII-2GQ1IRY63P
Atracurium Dibesylate

Biological Activity

[Description]:

tracurium (BW-33A free acid) is a potent, competitive and non-depolarizing neuromuscular blocking agent.Atracurium also is an AChR receptor antagonist. Atracurium induces bronchoconstriction and neuromuscular blockade. Atracurium promotes astroglial differentiation[1][2][3][4][5].

[Related Catalog]:

Research Areas >> Cardiovascular Disease
Signaling Pathways >> Membrane Transporter/Ion Channel >> nAChR
Signaling Pathways >> Neuronal Signaling >> nAChR
Research Areas >> Inflammation/Immunology

[In Vitro]

Atracurium (10 µM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells[4]. Atracurium (10 µM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs[4]. Atracurium (2.4 µM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells[5]. Cell Proliferation Assay[4] Cell Line: glioblastoma stem (GSC) cells Concentration: 3, 10, 20 µM Incubation Time: 72 h Result: Increased the percentage of GFP-positive cells in a dose-dependent manner from 5.3% in DMSO to 15.4%, 81.1%, and 86.8% in 3 μM, 10 μM, and 20 μM, respectively.

[In Vivo]

Atracurium (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice[2]. Atracurium (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats[3]. Animal Model: 5-12 weeks, 15-20 g male mice[2] Dosage: 1, 5, 10, 20, 50 mg/kg Administration: I.v. Result: Induced bronchoconstriction and Atracurium-induced airway hyperresponsiveness in DBA/2 mice was eliminated in a dose-dependent manner by pretreatment with atropine or pancuronium. Animal Model: 290 ± 30 g Male Sprague±Dawley rats (60 mg/kg heat-killed Corynebacteriumparvum for i.v.)[3] Dosage: 4.8 mg/kg Administration: I.v. Result: Induced neuromuscular blockade in Corynebacteriumparvum-injected rats.

[References]

[1]. Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9.

[2]. Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42.

[3]. Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604.

[4]. Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72.

[5]. Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14.

Chemical & Physical Properties

[ Melting Point ]:
185-194ºC

[ Molecular Formula ]:
C53H72N2O12++

[ Molecular Weight ]:
929.144

[ Exact Mass ]:
928.507446

[ PSA ]:
126.44000

[ LogP ]:
1.04

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NX5841000
CHEMICAL NAME :
Isoquinolinium, 1,2,3,4-tetrahydro-2,2'-(1,5-pentanediylbis(oxy(3-oxo -3,1-propanediyl)))bis (1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-2-meth yl-
CAS REGISTRY NUMBER :
64228-79-1
LAST UPDATED :
199612
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C53-H72-N2-O12
MOLECULAR WEIGHT :
929.27

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
520 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 287,247,1983

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.